Zinc transporters in prostate cancer

Franz, M.-C.; Anderle, P.; Bürzle, M.; Suzuki, Y; Freeman, M. R.; Hediger, M. A.; Kovacs, G. (2013). Zinc transporters in prostate cancer. Molecular aspects of medicine, 34(2-3), pp. 735-741. Elsevier 10.1016/j.mam.2012.11.007

Full text not available from this repository. (Request a copy)

Prostate cancer is a major health concern as it has the second highest incidence rate among cancers in men. Despite progress in tumor diagnostics and therapeutic approaches, prognosis for men with advanced disease remains poor. In this review we provide insight into the changes of the intermediary metabolism in normal prostate and prostate cancer. In contrast to normal cells, prostate cancer cells are reprogrammed for optimal energy-efficiency with a functional Krebs cycle and minimal apoptosis rates. A key element in this relationship is the uniquely high zinc level of normal prostate epithelial cells. Zinc is transported by the SLC30 and SLC39 families of zinc transporters. However, in prostate cancer the intracellular zinc content is remarkably reduced and expression levels of certain zinc transporters are altered. Here, we summarize the role of different zinc transporters in the development of prostate cancer.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine

UniBE Contributor:

Franz, Marie-Christine; Anderle, Pascale; Bürzle, Marc; Hediger, Matthias and Kovacs, Gergely


500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health








Patrizia Catucci

Date Deposited:

01 May 2014 12:28

Last Modified:

01 May 2014 12:28

Publisher DOI:


PubMed ID:




Actions (login required)

Edit item Edit item
Provide Feedback